Piramal Enterprises Limited

Veena R Agarwal

Giridharan Periyasamy

Swati Ajay Piramal

Muralidhara Padigaru

Gandhali Ashwin Deshpande

Sreesha Srinivasa

Maggie Rathos

Ankita Srivastava

Arun Balakrishnan

Robert Zahler

Rajiv Sharma

Sanjay Kumar

Bichismita Sahu

Nishigandha Naik

The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor.

Pharmaceutical combination for the treatment of melanoma

The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.

Compounds for the treatment of cancers associated with human papillomavirus

The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.

Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck

The present invention relates to substituted imidazo[4,5-c]quinoline derivatives, the compounds of formula (I), wherein R, R, R, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of formula (I), and their use in the treatment of diseases or disorders mediated by one or more kinases, particularly proliferative diseases or disorders such as cancer. These compounds can also be used in the treatment of inflammatory diseases and angiogenesis related disorders.

Substituted imidazoquinoline derivatives as kinase inhibitors

Growing community of inventors

Mumbai, India

Veena R Agarwal